Moderna-Merck Melanoma Vaccine Cuts Recurrence Risk by 42% in Landmark Trial

Key points

• Intismeran, a custom mRNA vaccine, reduced melanoma recurrence risk by 42% when combined with Merck's Keytruda.
• The trial included over 1,100 patients with high-risk melanoma, with 82% remaining recurrence-free at two years versus 70% on Keytruda alone.
• Moderna shares fell up to 25% after data leaked, despite positive results, as investors had already priced in success.
• The vaccine targets 34 specific tumor proteins, training the immune system to recognize cancer cells as foreign.
• Manufacturing takes about six weeks per patient, but companies aim to shorten this timeline for broader access.

Background

This development follows a period of mixed results in the cancer vaccine sector. In September 2026, early Phase 3 data for intismeran showed promise, but other mRNA cancer vaccines, such as BioNTech's BNT113, failed key endpoints in October 2026. The NIH also launched a public-private initiative in October 2026 to accelerate personalized cancer vaccine development, aiming to reduce development timelines from 8-15 years to 7-10 years. The current results provide a strong counterpoint to recent setbacks, reinforcing the potential of mRNA technology in oncology.

How outlets are covering it

AP News emphasizes the clinical success and the significance of the 42% reduction in recurrence, quoting researchers who call it a major win for the field. Time Magazine highlights the technical mechanism, noting that the vaccine trains the immune system to recognize 34 specific proteins, and includes commentary from Moderna's chief development officer on the replication of Phase 2 results. CNBC focuses on the market reaction, detailing the 25% drop in Moderna shares due to data leaks and the stock's 530% year-to-date rise. While all sources agree on the positive clinical data, they differ in emphasis: AP and Time focus on medical breakthroughs, while CNBC centers on financial volatility and investor expectations.

Why it matters

The success of intismeran validates the use of mRNA technology beyond infectious diseases, offering a new treatment pathway for cancer. It addresses a key limitation of current immunotherapies, which only work for about 30% of patients, by actively educating the immune system to recognize tumor cells. This could lead to broader applications in other cancers, such as lung and pancreatic, and potentially improve survival rates for high-risk melanoma patients.

What to watch

Moderna and Merck are in discussions with regulatory authorities regarding approval for intismeran. The companies are also conducting trials for the vaccine in other cancer types, including non-small cell lung cancer, pancreatic, and gastric cancer. Efforts are underway to shorten the six-week manufacturing timeline to make the treatment more accessible. Long-term outcomes from the trial are still being tracked, and overall survival data is not yet available.